<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-18_03-43-24</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>- If intolerable toxicity or ECOG ≥3, then adjust management from active systemic therapy to symptom‑focused best supportive care.  
- If clear radiologic progression or CA125 doubling, then adjust management from current regimen to next‑line systemic or trial strategy.  
- If significant response (tumor shrinkage, CA125 fall, symptoms improved), then adjust management from induction intensity to maintenance‑intensity systemic therapy.  
- If new organ dysfunction from metastases (e.g., liver failure, bowel obstruction), then adjust management from standard dosing to modified, palliative‑priority strategy.  
- If actionable biomarker emerges on repeat profiling, then adjust management from empiric chemotherapy to targeted/biomarker‑guided systemic approach.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）术后白紫+卡铂化疗6程，末次：2022.8.172022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)MR（2022.07.17）：2022.08.15：CA19-9:7.16U/ml,CA125:14.90U/ml,CA15-3:30.30U/ml↑,CEA:1.92ng/ml,HE4:87.90pmol/L↑,ROMA:23.55%(绝经前)↑,ROMA.:18.89%(绝经后)肿瘤标志物（2022.10.12）：CA19-9:77.20U/ml↑,CA125:89.60U/ml↑,AFP:&lt;0.91ng/ml,CEA:1.31ng/ml,HE4:59.70pmol/L,ROMA:12.07%(绝经前)↑,ROMA.:36.67%(绝经后)↑。CT（2022.10.25）：肝内多发结节，部分较前新见，转移可能，请结合MR检查。另见肝囊肿同前。MR（2022.10.24）：盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。盆腔系膜多发强化小结节，转移可能。2022.11.10外院血常规：白细胞 2.36，红细胞 3.56，血红蛋白 97，血小板 153外院生化：ALP　105，NA 136，PAB 1242022.11.30外院血常规：白细胞 3.46，红细胞 3.48，血红蛋白 94，血小板 1342022.11.17外院肿瘤指标：CA125　403，Ca153　63.8，Ca199 96.8，Ca724 695肿瘤标志物（2022.12.29）：CA19-9:229.00U/ml↑,CA125:933.00U/ml↑,CA15-3:86.00U/ml↑,CEA:1.49ng/ml,NSE:9.06ng/ml,HE4:111.00pmol/L↑,ROMA:41.02%(绝经前)↑,ROMA.:85.98%(绝经后)↑。MR（2022.12.30）：盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。右侧髂骨新见强化结节，转移可能。盆腔系膜多发强化小结节同前相仿，转移可能。直肠局部肠壁增厚伴强化。CT（2022.12.30）：肝内多发转移结节，较前增多，部分较前增大。另见肝囊肿同前。脾脏片状影，脾脏梗塞？随访。咨询报告</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;白紫+卡铂化疗&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;&lt;0.91 ng/ml (2022-10-12)&quot;,&quot;CA125&quot;:&quot;933.00 U/ml (2022-12-29)&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Recurrent ovarian cancer with pelvic presacral mass and hepatic metastases (imaging 2022-12-30)&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[],&quot;histology&quot;:&quot;透明细胞癌&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;Recurrent ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Unknown&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;白紫+卡铂化疗&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Unknown&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Unknown&quot;,&quot;regimens&quot;:[],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;56&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;56&quot;,&quot;end_date&quot;:&quot;2022-08-17&quot;,&quot;evidence&quot;:&quot;CA125 increased to 89.60 U/ml on 2022-10-12 after last carboplatin-containing chemo ended 2022-08-17&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;start_date&quot;:&quot;Unknown&quot;,&quot;status&quot;:&quot;Resistant&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;56&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Resistant&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Resistant&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;evidence&quot;:&quot;CA125 increased to 89.60 U/ml on 2022-10-12; subsequent imaging 2022-10-24/25 suggested pelvic recurrence and liver metastases&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;SCENE&quot;:&quot;Platinum_resistant_relapse&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Cytoreductive surgery including partial rectosigmoid colectomy, partial vaginectomy, retroperitoneal lesion resection, complex lysis of intestinal adhesions, left ureteral stent placement, bladder repair&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery for recurrent ovarian cancer; specimens from partial rectosigmoid, left retroperitoneal tumor, partial vagina&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Pathology: intestinal wall full-thickness high-grade adenocarcinoma; considered consistent with ovarian clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂 chemotherapy; last administration recorded&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last chemo date 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂化疗&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical evidence of relapse with rising tumor markers&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 89.60 U/ml; CA19-9 77.20 U/ml; HE4 59.70 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MR: postoperative presacral mass increased, possible recurrence with adjacent sacral involvement; pelvic mesenteric nodules suspicious for metastasis&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Right iliac bone new enhancing nodule; presacral mass increased&quot;,&quot;regimen_or_test&quot;:&quot;MR pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new compared with prior, suggesting metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MR/CT: pelvic presacral mass larger and more heterogeneously enhancing; increased number and size of hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and liver disease&quot;,&quot;regimen_or_test&quot;:&quot;MR pelvis and CT abdomen&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-03&quot;,&quot;first_relapse_date&quot;:&quot;2022-10-12&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-08-17&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;45.7&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;14.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;89.60&quot;},{&quot;date&quot;:&quot;2022-11-17&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;403&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;933.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;562&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;87.90&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;59.70&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;111.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;161&quot;},{&quot;date&quot;:&quot;2022-08-15&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.16&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;77.20&quot;},{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-12-29&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;229.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;&lt;0.91&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery performed&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Last dose of 白紫+卡铂 chemotherapy (cycle 6)&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical relapse with CA125 rise&quot;,&quot;type&quot;:&quot;Relapse&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;6 cycles completed (last on 2022-08-17)&quot;,&quot;last_admin_date&quot;:&quot;2022-08-17&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;白紫+卡铂化疗6程&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;部分直乙结肠&quot;,&quot;左侧腹膜后肿瘤&quot;,&quot;部分阴道&quot;],&quot;date&quot;:&quot;2022-03-28&quot;,&quot;diagnosis&quot;:&quot;卵巢透明细胞癌累及&quot;,&quot;grade&quot;:&quot;高级别腺癌&quot;,&quot;ihc&quot;:[{&quot;marker&quot;:&quot;MLH1(ES05)&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH6&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;MSH2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;PMS2&quot;,&quot;result&quot;:&quot;(+)&quot;},{&quot;marker&quot;:&quot;ER&quot;,&quot;result&quot;:&quot;（部分+）&quot;},{&quot;marker&quot;:&quot;PR&quot;,&quot;result&quot;:&quot;（少弱+）&quot;},{&quot;marker&quot;:&quot;P53&quot;,&quot;result&quot;:&quot;（+/-）&quot;},{&quot;marker&quot;:&quot;WT1&quot;,&quot;result&quot;:&quot;（-）&quot;},{&quot;marker&quot;:&quot;Ki-67&quot;,&quot;result&quot;:&quot;（60%+）&quot;},{&quot;marker&quot;:&quot;HNF1B&quot;,&quot;result&quot;:&quot;（+）&quot;},{&quot;marker&quot;:&quot;NapsinA&quot;,&quot;result&quot;:&quot;（灶+）&quot;},{&quot;marker&quot;:&quot;P16&quot;,&quot;result&quot;:&quot;（+）&quot;},{&quot;marker&quot;:&quot;PAX8&quot;,&quot;result&quot;:&quot;（+）&quot;},{&quot;marker&quot;:&quot;SALL4&quot;,&quot;result&quot;:&quot;（-）&quot;},{&quot;marker&quot;:&quot;ZBTB16&quot;,&quot;result&quot;:&quot;（-）&quot;}],&quot;involvement_sites&quot;:[&quot;intestinal wall full-thickness&quot;,&quot;left retroperitoneal tumor&quot;,&quot;vaginal tissue&quot;],&quot;laterality&quot;:&quot;Unknown&quot;,&quot;molecular&quot;:[],&quot;raw_text&quot;:&quot;卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562\n2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）&quot;,&quot;sample_type&quot;:&quot;Surgical specimen&quot;,&quot;site&quot;:&quot;部分直乙结肠; 左侧腹膜后肿瘤; 部分阴道&quot;,&quot;tumor_size&quot;:&quot;7*4*2.5cm&quot;,&quot;uncertainty_or_missing&quot;:[]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-24&quot;,&quot;findings&quot;:[&quot;Postoperative presacral mass increased in size and heterogenous enhancement&quot;,&quot;Pelvic mesenteric multiple enhancing small nodules, suspicious for metastasis&quot;,&quot;Right iliac bone new enhancing nodule&quot;],&quot;impression&quot;:&quot;Consider recurrence with adjacent sacral involvement and pelvic/peritoneal metastases&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Multiple hepatic nodules, some new compared with prior, suggest metastases&quot;,&quot;Hepatic cysts unchanged&quot;],&quot;impression&quot;:&quot;Multiple liver metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Postoperative presacral mass larger, more heterogeneous enhancement&quot;,&quot;Pelvic mesenteric enhancing nodules increased or similar&quot;],&quot;impression&quot;:&quot;Enlarged presacral recurrent mass with possible adjacent peritoneal and sacral involvement&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;,&quot;Spleen&quot;],&quot;date&quot;:&quot;2022-12-30&quot;,&quot;findings&quot;:[&quot;Multiple intrahepatic metastatic nodules increased in number and size&quot;,&quot;Focal splenic abnormality described (possible infarct)&quot;],&quot;impression&quot;:&quot;Progression of hepatic metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Worse&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2022-03-28&quot;,&quot;description&quot;:&quot;Cytoreductive surgery for recurrent ovarian cancer; specimens from partial rectosigmoid, left retroperitoneal tumor, partial vagina&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Pathology: intestinal wall full-thickness high-grade adenocarcinoma; considered consistent with ovarian clear cell carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-08-17&quot;,&quot;description&quot;:&quot;Completed 6 cycles of 白紫+卡铂 chemotherapy; last administration recorded&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Last chemo date 2022-08-17&quot;,&quot;regimen_or_test&quot;:&quot;白紫+卡铂化疗&quot;},{&quot;date&quot;:&quot;2022-10-12&quot;,&quot;description&quot;:&quot;Biochemical evidence of relapse with rising tumor markers&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 89.60 U/ml; CA19-9 77.20 U/ml; HE4 59.70 pmol/L&quot;,&quot;regimen_or_test&quot;:&quot;Tumor markers&quot;},{&quot;date&quot;:&quot;2022-10-24&quot;,&quot;description&quot;:&quot;Pelvic MR: postoperative presacral mass increased, possible recurrence with adjacent sacral involvement; pelvic mesenteric nodules suspicious for metastasis&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Right iliac bone new enhancing nodule; presacral mass increased&quot;,&quot;regimen_or_test&quot;:&quot;MR pelvis&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;CT: multiple hepatic nodules, some new compared with prior, suggesting metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Multiple liver metastatic nodules&quot;,&quot;regimen_or_test&quot;:&quot;CT abdomen&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;MR/CT: pelvic presacral mass larger and more heterogeneously enhancing; increased number and size of hepatic metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Progression of pelvic and liver disease&quot;,&quot;regimen_or_test&quot;:&quot;MR pelvis and CT abdomen&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Severe anemia (Hgb 74 g/L) needs urgent work‑up and correction before or alongside any new systemic regimen planning.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please confirm extent of presacral/sacral, hepatic, peritoneal, and possible bone involvement and whether additional chest or spine imaging is recommended now.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Do we have any MSI/MMR, TMB, or PD‑L1 results from recurrent tissue, or is new biopsy/molecular profiling feasible?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Would PET/CT materially refine staging or trial eligibility in this widely metastatic, platinum‑resistant setting, or add little beyond CT/MRI?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Latest available imaging is from 2022-12-29/30 and already shows clear systemic progression; updated whole-body restaging (incl. chest and bone assessment) is needed to guide current palliative planning and pain risk assessment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Key pathology-based biomarkers (MMR, HRD, BRCA1/2) are already available, but absence of MSI/TMB/PD-L1 and recurrent-tissue NGS may limit systemic and trial planning; confirming whether additional sampling/testing is practical in this platinum-resistant, palliative context is important for MDT decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>MMR proficiency and HRD-negative status are established, but MSI/TMB/PD-L1 and any NGS on recurrent tissue remain undocumented; if further systemic options or trial eligibility are being considered, updated molecular profiling on the most recent tumor should be obtained if feasible.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>No PET/CT has been performed yet; if trial eligibility or precise metastatic mapping is relevant, a whole-body FDG PET/CT is still needed.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>From nuclear perspective, current staging relies only on MR/CT; please confirm if any interim PET/CT or chest imaging exists or is scheduled.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Given platinum-resistant clear cell histology and palliative intent, we should prioritize clarifying ECOG, symptoms, and goals before committing to further systemic therapy or PET/CT.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Before considering PET/CT, can you confirm availability and adequacy of recent chest and spine imaging to document pulmonary and bone status?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Agree MMR/HRD/BRCA are done; please advise on feasibility and expected turnaround for MSI/TMB/PD-L1 and updated NGS on the most recent tumor sample.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>If adequate CT/MRI chest/abdomen/pelvis and spine can be obtained, would PET/CT meaningfully alter systemic or trial decisions in this case?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>No PET/CT or recent dedicated chest imaging is documented; from radiology side, updated whole-body CT or PET/CT restaging is advisable if management may change.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before committing to further systemic therapy or PET/CT, we must urgently clarify ECOG, symptom burden, goals, and correct the severe anemia.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please confirm whether any recent chest/spine imaging exists; if absent, advise whether comprehensive CT versus PET/CT would better support treatment/trial decisions.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Given platinum-resistant, biomarker-negative clear cell disease, please confirm if recurrent-tissue MSI/TMB/PD-L1 and expanded NGS are feasible with acceptable turnaround.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>In this widely metastatic, palliative setting, would PET/CT provide management-changing information beyond optimized CT/MRI for systemic or trial planning?</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>No chest or spine imaging is documented after 2022-12 CT/MR abdomen/pelvis; a contrast-enhanced chest/abdomen/pelvis CT with targeted spine evaluation should suffice for restaging unless a specific trial mandates PET/CT.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>From pathology side, MSI/MMR proteins are intact; MSI/TMB/PD-L1 and expanded NGS on recurrent tissue are not yet documented and feasibility/turnaround will depend on confirming an adequate recent block (tumor content, fixation) with the originating lab.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>In this widely metastatic, palliative setting, PET/CT is most useful if it would alter trial eligibility or focal radiotherapy plans; otherwise optimized contrast CT/MRI is usually sufficient for systemic decision-making.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Confirm performance status, symptoms, patient goals; discuss palliative vs disease-directed intent given progressive presacral and liver metastases [@2022-12-29|MR;2022-12-29|CT].  \n- Treat as platinum‑resistant recurrent clear cell ovarian cancer; plan non‑platinum systemic therapy and consider clinical trial enrollment.  \n- Address severe anemia urgently (Hgb 74 g/L) with cause evaluation and correction before or during further systemic therapy [@20230103|5600862].  \n- No actionable HRD/BRCA found; consider broader molecular profiling of recurrent tissue if feasible to identify additional targets [@OH2203828].  \n- Clarify current performance status, comorbidities, pain control, prior toxicities, and any maintenance therapies given, before finalizing regimen and sequencing.&quot;,
  &quot;oncologist&quot;: &quot;- Biochemical and radiologic relapse within ~2 months of completing platinum suggests platinum-resistant recurrent clear cell ovarian carcinoma.  \n\n- Current disease is metastatic (pelvis, liver); systemic therapy now palliative/relapse setting rather than adjuvant. [@20221229|9703212; 2022-12-30 imaging per case view]  \n\n- Organ function appears adequate for systemic therapy; hepatic and renal parameters acceptable. [@20221229|8300002]  \n\n- Significant anemia (HGB 74 g/L) requires evaluation and correction before or during next-line systemic treatment. [@20230103|5600862]  \n\n- Missing/needs update today: ECOG performance status, current symptoms, full staging scan reports, prior regimen tolerability, and patient treatment goals/preferences.&quot;,
  &quot;radiologist&quot;: &quot;- Enlarging 5.3×4.4 cm presacral postoperative mass with heterogeneous enhancement, suspicious for local pelvic recurrence and sacral involvement [@2022-12-29|MR].  \n\n- Multiple enhancing pelvic mesenteric nodules, overall similar/slightly increased, consistent with peritoneal/mesenteric metastases [@2022-12-29|MR].  \n\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis [@2022-12-29|MR].  \n\n- Multiple hepatic metastatic nodules increased in number and size versus October, indicating progressive liver metastases [@2022-12-29|CT].  \n\n- New focal splenic low-density area possibly infarct; recommend clinical correlation and imaging follow-up [@2022-12-29|CT].&quot;,
  &quot;pathologist&quot;: &quot;- Current diagnosis: recurrent ovarian clear cell carcinoma involving rectosigmoid, left retroperitoneum, and vagina; high‑grade adenocarcinoma morphology [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- IHC supports MMR proficiency (MLH1/MSH2/MSH6/PMS2 all retained), excluding overt MMR-deficient phenotype [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Clear cell phenotype corroborated by HNF1B+, focal Napsin A+, PAX8+, WT1–, ER/PR low, Ki‑67 ~60% [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Germline ATM p.Y316C detected; HRD negative; no pathogenic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA variants [@OH2203828|2022-04-18].  \n\n- Missing: updated stage at recurrence, contemporary imaging, MSI/TMB/PD‑L1 results on recurrent tumor, and any newer molecular profiling.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT available; metabolic pattern, current stage by PET, and PET evidence of recurrence are unknown/need update.  \n\n- Prior MR shows enlarging presacral mass with sacral and peritoneal involvement, highly suspicious for local recurrent pelvic disease [@2022-12-29|MR].  \n\n- Pelvic mesenteric nodules and right iliac bone nodule suggest additional metastatic sites beyond local presacral recurrence [@2022-12-29|MR].  \n\n- CT demonstrates multiple progressive liver metastases, confirming distant metastatic spread and at least M1 disease [@2022-12-29|CT].  \n\n- A new whole-body FDG PET/CT is needed now to clarify full metastatic burden and guide current staging.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Prioritize non-platinum systemic therapy for platinum-resistant clear cell ovarian cancer with pelvic and liver progression [@2022-12-29|MR; @2022-12-29|CT].  \n- Correct significant anemia before/early during treatment; evaluate iron, B12/folate, bleeding, hemolysis causes [HGB 74 g/L, @20230103|5600862].  \n- Obtain updated performance status, symptoms, and patient goals to balance treatment intensity vs quality-of-life; current status unknown.  \n- Reconfirm molecular profile on recent tumor if feasible; current HRD–, BRCA1/2–, ATM Y316C germline noted [@OH2203828|2022-04-18].  \n- Plan close monitoring with serial CA125 and imaging to assess response; latest CA125 933 U/ml [@20221229|9703212].&quot;,
    &quot;oncologist&quot;: &quot;- Confirm ECOG status, symptom burden, comorbidities, and patient goals to guide palliative versus disease‑directed systemic therapy (details currently unknown).  \n\n- Urgently evaluate and treat severe anemia (HGB 74 g/L) with iron, nutritional, hemolysis, and bleeding work‑up. [@20230103|5600862]  \n\n- Obtain updated whole‑body imaging (CT or PET/CT including chest and spine) for formal restaging if results will influence therapy or trial options (no recent staging documented).  \n\n- Request feasibility and turnaround for MSI/TMB/PD‑L1 and broader NGS on most recent/recurrent tissue to expand systemic and trial options (currently undocumented). [@OH2203828|2022-04-18]  \n\n- Plan non‑platinum systemic regimen appropriate for platinum‑resistant clear cell disease once performance status, anemia management, and updated staging/biomarkers are clarified.&quot;,
    &quot;radiologist&quot;: &quot;- Disease shows clear progression with enlarging presacral mass, mesenteric/peritoneal nodules, liver and possible bone metastases [@2022-12-29|MR; @2022-12-29|CT].  \n\n- No PET/CT or recent dedicated chest imaging documented; whole-body CT or PET/CT should be considered for up-to-date staging [unknown].  \n\n- Sacral and right iliac bone involvement risk skeletal events and pain; spine/pelvic imaging refinement is advisable for symptom-focused planning [@2022-12-29|MR].  \n\n- Splenic low-density area may represent infarct; correlate with symptoms and consider follow-up imaging if clinically relevant [@2022-12-29|CT].  \n\n- Future systemic or trial decisions require updated imaging baseline before starting additional palliative therapy or local interventions [@2022-12-29|MR; @2022-12-29|CT].&quot;,
    &quot;pathologist&quot;: &quot;- Diagnosis: platinum‑resistant recurrent high‑grade ovarian clear cell carcinoma, MMR‑proficient, HRD‑negative, BRCA1/2 wild type [@HISTOLOGY_AND_IHC|2022-03-28][@OH2203828|2022-04-18].  \n\n- No MSI/TMB/PD‑L1 or recurrent‑tissue NGS documented; clarify tissue availability and arrange extended profiling if aligned with goals [@MOLECULAR|unknown].  \n\n- Ensure pathology confirms which block represents latest recurrence and suitability (tumor content, fixation) for additional molecular tests [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Coordinate with oncology on urgency: balance turnaround times for MSI/TMB/PD‑L1/NGS against patient status and palliative intent [@OH2203828|2022-04-18].  \n\n- Germline ATM p.Y316C is reported without clear pathogenic classification; consider genetics input regarding its significance [@OH2203828|2022-04-18].&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT is available; metabolic staging and PET confirmation of recurrence remain unknown/need update [@2022-12-29|MR][@2022-12-29|CT].  \n\n- MR shows enlarging presacral mass with sacral/peritoneal involvement, strongly suggesting metabolically active local recurrence [@2022-12-29|MR].  \n\n- MR suggests pelvic mesenteric and right iliac bone metastases, where PET/CT could better define true extent [@2022-12-29|MR].  \n\n- CT confirms progressive multifocal liver metastases; PET/CT would refine lesion burden but may not change systemic intent [@2022-12-29|CT].  \n\n- If trial eligibility or radiotherapy targeting is considered, whole-body FDG PET/CT is recommended for comprehensive metabolic mapping.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Classify as platinum-resistant recurrent ovarian clear cell carcinoma with progressive pelvic and hepatic metastases [@2022-12-29|MR; @2022-12-29|CT].  \n- Before final regimen: document ECOG, symptoms, prior toxicities, fertility goals, and discuss palliative intent and trial interest (all unknown).  \n- Initiate non-platinum systemic therapy ± targeted agent, considering liver function preserved and severe anemia requiring correction [@20221229|8300002; @20230103|5600862].  \n- Refer to radiation/surgical teams only for symptom-focused local control (pain, bleeding, obstruction) based on current presacral/osseous disease [@2022-12-29|MR].  \n- Arrange close follow-up with CA125/HE4, CBC, LFTs and symptom review to judge benefit vs toxicity and stop if futile [@20221229|9703212; @20221229|8300002; @20230103|5600862].&quot;,
    &quot;oncologist&quot;: &quot;- Confirm ECOG status, symptom burden, comorbidities, and goals to choose between further systemic therapy versus best‑supportive‑care‑focused approach (currently unknown).  \n\n- Urgently investigate and correct severe anemia (Hgb 74 g/L) before starting new systemic therapy; assess iron/B12/folate, hemolysis, bleeding. [@20230103|5600862]  \n\n- Arrange contrast CT chest/abdomen/pelvis with targeted spine evaluation for restaging; reserve PET/CT only if required for trial/radiotherapy. [@20221229|8300002]  \n\n- Verify availability/adequacy of recurrent-tissue block and proceed with MSI/TMB/PD‑L1 and expanded NGS if feasible to broaden options. [@OH2203828|2022-04-18]  \n\n- After PS, anemia, and imaging clarified, select non‑platinum palliative systemic regimen or clinical trial, reassessing benefit versus toxicity continuously.&quot;,
    &quot;radiologist&quot;: &quot;- Imaging shows progressive presacral recurrence with sacral, pelvic mesenteric/peritoneal and hepatic metastases; possible bone and splenic involvement [@2022-12-29|MR; @2022-12-29|CT].  \n\n- No chest or spine imaging or PET/CT documented after 2022-12; comprehensive contrast CT chest/abdomen/pelvis with spine assessment is needed for restaging [unknown].  \n\n- PET/CT may be reserved for situations where additional metabolic mapping would change trial eligibility or focal radiotherapy planning [unknown].  \n\n- Sacral and right iliac bone involvement risk skeletal complications; targeted spine/pelvic imaging will support pain and stability management [@2022-12-29|MR].  \n\n- Splenic low-density area may represent infarct; repeat imaging can clarify evolution if clinically indicated [@2022-12-29|CT].&quot;,
    &quot;pathologist&quot;: &quot;- Confirm ECOG, symptom burden, comorbidities, and patient goals before further systemic therapy or PET/CT [@MOLECULAR|unknown].  \n\n- Investigate and urgently correct severe anemia (Hgb 74 g/L) in parallel with oncologic planning [@MOLECULAR|unknown].  \n\n- Restage with contrast-enhanced CT chest/abdomen/pelvis including targeted spine evaluation; reserve PET/CT for trial or radiotherapy decisions [@MOLECULAR|unknown].  \n\n- Plan non‑platinum systemic therapy for platinum‑resistant ovarian clear cell carcinoma, contingent on performance status and patient priorities [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Verify availability of adequate recent tumor block and, if feasible, perform MSI/TMB/PD‑L1 and expanded NGS to broaden options [@OH2203828|2022-04-18].&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT has been performed; metabolic staging and PET assessment of recurrence remain unknown/need update [@2022-12-29|MR][@2022-12-29|CT].  \n\n- MR shows enlarging presacral mass with adjacent sacral and peritoneal involvement, consistent with metabolically active local recurrence [@2022-12-29|MR].  \n\n- MR suggests pelvic mesenteric and right iliac bone metastases, where PET/CT could better delineate true extent and activity [@2022-12-29|MR].  \n\n- CT demonstrates progressive multifocal liver metastases; PET/CT would refine lesion burden but is unlikely to change systemic palliative intent [@2022-12-29|CT].  \n\n- Reserve whole-body FDG PET/CT for situations where results would directly impact trial eligibility or focal radiotherapy planning.&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-03</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-03</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-04-18</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-12-29</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20221229|8300002&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;天冬氨酸氨基转移酶 43.0 U/L (AST)\n游离脂肪酸 0.09 mmol/L (NEFA)\n谷氨酸脱氢酶 4.1 U/L (GLDH)\n白蛋白 36.7 g/l (ALB)\n总蛋白 67.0 g/l (TP)\n谷草同工酶 12.7 U/L (ASTM)\n球蛋白 30.3 g/l (GELO)\n直接胆红素 3.2 umol/l (DBIL)\n尿酸 146 umol/l (UA)\n总胆红素 5.1 umol/l (TBIL)\n前白蛋白 98 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n碱性磷酸酶 100.0 U/L (ALP)\n丙氨酸氨基转移酶 40.8 U/l (ALT)\n肌酐 49 umol/l (CRE)\n白球比例 1.21 nan (A/G)\n乳酸脱氢酶 254 U/L (LDH)\n尿素 4.67 mmol/l (UREA)\nγ-谷氨酰基转移酶 38 U/L (GGT)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20221229|9703212&quot;,
        &quot;date&quot;: &quot;2022-12-29T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;神经元特异烯醇化酶 9.06 ng/ml (NSE)\n卵巢恶性肿瘤风险值. 85.98 %(绝经后) (ROMA.)\n糖链抗原15-3 86.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 41.02 %(绝经前) (ROMA)\n人附睾蛋白4 111.00 pmol/L (HE4)\n癌胚抗原 1.49 ng/ml (CEA)\n糖链抗原125 933.00 U/ml (CA125)\n糖链抗原19-9 229.00 U/ml (CA19-9)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230103|5600862&quot;,
        &quot;date&quot;: &quot;2023-01-03T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;中性粒细胞% 76.5 % (GRAN)\nPLT分布宽度 12 % (PDW)\n嗜碱性细胞数 0.01 *10^9/L (BASO#)\n嗜碱性细胞% 0.20 % (BASO)\n淋巴细胞数 0.5 *10^9/L (LYM#)\n中性粒细胞数 4.8 *10^9/L (GRAN#)\n红细胞计数 2.84 *10^12/L (RBC)\n血小板计数 259 *10^9/L (PLT)\nRBC分布宽度-CV 18.6 % (RDWCV)\n平均红细胞血红蛋白浓度 305.0 g/l (MCHC)\n血小板压积 0.28 % (PCT)\nRBC分布宽度-SD 57 nan (RDWSD)\n单核细胞数 0.9 *10^9/L (MID#)\n自动审核标志 UNACCEPT nan (VFLAG)\n平均红细胞体积 85.6 fl (MCV)\n白细胞计数 6.2 *10^9/L (WBC)\n血红蛋白量 74 g/l (HGB)\n嗜酸性细胞数 0.00 *10^9/L (EOS#)\n嗜酸性细胞% 0.00 % (EOS)\n淋巴细胞% 8.5 % (LYM)\n单核细胞% 14.8 % (MID)\n平均红细胞血红蛋白量 26.1 pg (MCH)\n红细胞比积 24.3 % (HCT)\n平均PLT容积 10.9 fl (MPV)\n中性淋巴比值 9.60 nan (NL)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;对比2022-7-16：盆腔术后，阴道残端略厚，骶前见不规则肿块影，相邻骶骨受累，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚，膀胱内可疑少许积气本次不明显。 盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。 盆腔系膜多发强化小结节，转移可能。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;对比2022-7-16：盆腔术后，阴道残端略厚，骶前见不规则肿块影，相邻骶骨受累，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚，膀胱内可疑少许积气本次不明显。 盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。 盆腔系膜多发强化小结节，转移可能。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-10-24|MR&quot;,
        &quot;date&quot;: &quot;2022-10-24T15:52:25&quot;,
        &quot;raw_text&quot;: &quot;对比2022-7-16：盆腔术后，阴道残端略厚，骶前见不规则肿块影，相邻骶骨受累，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚，膀胱内可疑少许积气本次不明显。 盆腔术后，骶前占位，考虑复发伴相邻骶骨受累可能。 盆腔系膜多发强化小结节，转移可能。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|MR&quot;,
        &quot;date&quot;: &quot;2022-12-29T12:39:55&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：盆腔术后，阴道残端略厚，骶前见不规则肿块影，较前增大，目前范围约53×44mm，信号较前不均，相邻腹膜、骶骨受累，右侧髂骨新见强化结节，直肠局部肠壁增厚伴强化。膀胱充盈可，壁未见明显增厚。 盆腔术后，骶前占位范围较前增大、较前强化不均，考虑复发伴相邻腹膜、骶骨受累可能，请结合临床。 右侧髂骨新见强化结节，转移可能。 盆腔系膜多发强化小结节同前相仿，转移可能。 直肠局部肠壁增厚伴强化。&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-12-29|CT&quot;,
        &quot;date&quot;: &quot;2022-12-29T15:52:40&quot;,
        &quot;raw_text&quot;: &quot;对比前片2022-10-21：肝内多发低密度结节，较前增多，部分较前增大，大者约17m*14mm，部分较前新见。肝内另见多发囊性无强化结节同前。肝内血管走行正常，肝内外胆管无扩张，脾脏片状低密度影、胆囊、胰腺大小形态及密度正常，双侧肾脏对称，大小及形态正常。腹膜后未见肿大淋巴结，腹腔内未见积液。 肝内多发转移结节，较前增多，部分较前增大。 另见肝囊肿同前。 脾脏片状影，脾脏梗塞？随访。&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2203828&quot;,
        &quot;date&quot;: &quot;2022-04-18T14:11:19&quot;,
        &quot;raw_text&quot;: &quot;ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>Recurrent platinum-sensitive ovarian clear cell carcinoma post-cytoreduction and carbo-based chemo, now with enlarging presacral mass plus liver and possible bone/peritoneal metastases; MMR-proficient, ER/PR low-positive; organ function and performance status for further systemic therapy?</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>RAG Evidence Pack (top=5):
[1] score=0.6603 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCC…
[2] score=0.6461 nccn_ovariancancer_v3_2025__v00000000 [PAGE 14]
    ff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of disease; clinical judgment and flexibility should be utilized in determining treatment options. gg Data are limited on primary and maintenance therapy for recurrent/ persistent LCOC. hh During and after treat…
[3] score=0.6393 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 4]
    procedures.20 Systemic therapy Adjuvant platinum-based ChT signiﬁcantly prolongs OS and PFS in patients with early-stage EOC, as demonstrated in the joint analysis of ACTION and ICON1 trials and a Figure 1. Management of early EOC (FIGO stage I-II). See Supplementary Table S1, available at https://d…
[4] score=0.6374 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15]
    n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). dd Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Tumor molecular analysis is recommended to include, at a minimum, tests to identify potent…
[5] score=0.6304 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 10]
    with ﬁrst line. This can probably be explained by an accu- mulative exposure to platinum.85 Several factors need to be taken into consideration for the selection of PARPis or anti-VEGF therapies in relapse including histotype, BRCA1/2-mut status, prior therapies (PARPi and/or bevacizumab), expected …</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.660261869430542,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\n• Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n ◊If not previously used (category 1)\n ◊If disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6461338996887207,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 14,
    &quot;text&quot;: &quot;ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6393470764160156,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 4,
    &quot;text&quot;: &quot;procedures.20\nSystemic therapy\nAdjuvant platinum-based ChT signiﬁcantly prolongs OS and\nPFS in patients with early-stage EOC, as demonstrated in\nthe joint analysis of ACTION and ICON1 trials and a\nFigure 1. Management of early EOC (FIGO stage I-II).\nSee Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2023.07.011, for a summary of the beneﬁt of adjuvant systemic therapy for early EOC (FIGO\nI-II stage).\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; white: other aspects of management; dashed lines: optional therapy.\nCCC, clear-cell carcinoma; ChT, chemotherapy; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics;\nHGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma.\nAnnals of Oncology\nA. González-Martín et al.\n836\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6373691558837891,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6304485201835632,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.&quot;
  }
]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- For first recurrence after prior platinum-based chemotherapy, immediate platinum-based combination therapy is preferred when feasible; secondary cytoreductive surgery can be considered in selected patients, and best supportive care remains an option alongside or instead of systemic therapy [NCCN_ovariancancer_v3_2025 p15].  
- Treatment of recurrent disease should be individualized along a spectrum of platinum sensitivity vs resistance; rigid cut-offs are discouraged and clinical judgment is required when selecting systemic therapy and sequencing options [NCCN_ovariancancer_v3_2025 p14].  
- For low-grade or less common ovarian cancer histologies (e.g. LCOC), evidence for both primary and maintenance systemic therapy in the recurrent/persistent setting is limited, so extrapolation from high-grade serous data should be cautious and preferably within expert centers or trials [NCCN_ovariancancer_v3_2025 p14].  
- Validated molecular testing on the most recent available tumor tissue is recommended at recurrence, including at minimum assays to identify potential therapeutic targets (e.g. BRCA1/2 and other HRR genes, MSI/MMR, and other actionable alterations) to guide systemic and maintenance strategies [NCCN_ovariancancer_v3_2025 p15].  
- Adjuvant platinum-based chemotherapy significantly improves overall and progression-free survival in early-stage epithelial ovarian cancer (FIGO I–II), supporting platinum use as foundational systemic therapy and influencing subsequent relapse management strategies [ESMO_CPG_epithelialOvarian_2023 p4].  
- In the relapse setting, choice between PARP inhibitors and anti-VEGF therapies should integrate histologic subtype, BRCA1/2 mutation/HRD status, prior exposure to PARP inhibitors and/or bevacizumab, and cumulative platinum exposure, as these factors influence expected benefit and toxicity [ESMO_CPG_epithelialOvarian_2023 p10].  
- Reduced efficacy of PARP inhibitors is observed when used after extensive prior platinum and/or prior PARP exposure, so earlier-line use in appropriately selected patients is generally favored over reserving PARP for late relapse [ESMO_CPG_epithelialOvarian_2023 p10].  
- During and after treatment for recurrent disease, ongoing assessment of symptom burden, performance status, and patient preference is essential to decide between further active systemic therapy, clinical trial participation, or transition to best supportive care [NCCN_ovariancancer_v3_2025 p14–15].</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-18T03:38:14.290767&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-03 08:53:29.260000&quot;,
      &quot;meta_info&quot;: &quot;340123197709263626&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:38:14.291117&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;adcf9c7fb435&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:38:14.637572&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 92,
      &quot;img_n&quot;: 10,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-04 08:53:29&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:38:53.914997&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20221229|8300002|2022-12-29&quot;,
          &quot;20221229|9703212|2022-12-29&quot;,
          &quot;20230103|5600862|2023-01-03&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-10-24|MR|2022-10-24&quot;,
          &quot;2022-12-29|MR|2022-12-29&quot;,
          &quot;2022-12-29|CT|2022-12-29&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2203828|2022-04-18&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:39:18.253008&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Recurrent platinum-sensitive ovarian clear cell carcinoma post-cytoreduction and carbo-based chemo, now with enlarging presacral mass plus liver and possible bone/peritoneal metastases; MMR-proficient, ER/PR low-positive; organ function and performance status for further systemic therapy?&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:39:18.253018&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:39:30.306595&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:43:20.879607&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 3915
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:43:20.880751&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-18T03:43:24.208808&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 767
    }
  }
]</pre>
  </details>

</body>
</html>
